ECOG-ACRIN Cancer Research Group
@eaonc.bsky.social
Biomarker-driven medical research involving adults who have or are at risk of developing cancer
Pinned
Beating the odds: Steven Merlin’s journey through pancreatic cancer and clinical trials
An inspiring interview with a 13-year survivor of stage 4 pancreas cancer
bit.ly
After being diagnosed with #PancreaticCancer, Steven Merlin found hope through a #clinicaltrial. Now as an ECOG-ACRIN advocate, he shares his perspective on the benefits of clinical trials. Read his inspiring story: bit.ly/beatingtheod...
Reposted by ECOG-ACRIN Cancer Research Group
The NCI myeloMATCH precision medicine trial portfolio in myeloid cancers is highlighted in numerous presentations at the upcoming #ASH25 meeting. Learn more:
dctd.cancer.gov/about/news-e...
@swog.org @eaonc.bsky.social @cctg.bsky.social #NCORP
dctd.cancer.gov/about/news-e...
@swog.org @eaonc.bsky.social @cctg.bsky.social #NCORP
December 1, 2025 at 1:46 PM
The NCI myeloMATCH precision medicine trial portfolio in myeloid cancers is highlighted in numerous presentations at the upcoming #ASH25 meeting. Learn more:
dctd.cancer.gov/about/news-e...
@swog.org @eaonc.bsky.social @cctg.bsky.social #NCORP
dctd.cancer.gov/about/news-e...
@swog.org @eaonc.bsky.social @cctg.bsky.social #NCORP
On #WorldPancreaticCancerDay 💜 we are shining a light on two @eaonc.bsky.social clinical trials aiming to improve outcomes for patients with #PancreaticCancer & #PancreaticCysts - EA2185 and EA2192/APOLLO. Learn more here 👉 bit.ly/pancreaticf25
Ongoing Trials: A closer look at ECOG-ACRIN’s clinical trials for patients with pancreatic conditions
For Pancreatic Cancer Awareness Month, we highlight two actively recruiting clinical trials for patients with pancreatic conditions
bit.ly
November 20, 2025 at 4:51 PM
On #WorldPancreaticCancerDay 💜 we are shining a light on two @eaonc.bsky.social clinical trials aiming to improve outcomes for patients with #PancreaticCancer & #PancreaticCysts - EA2185 and EA2192/APOLLO. Learn more here 👉 bit.ly/pancreaticf25
Can patients with high-risk retroperitoneal #sarcoma benefit from neoadjuvant chemotherapy? The international EA7211/STRASS 2 #ClinicalTrial, led in the US by Dr. Kenneth Cardona, aims to find out. More: bit.ly/EA7211 #leiomyosarcoma #liposarcoma
November 17, 2025 at 6:29 PM
Can patients with high-risk retroperitoneal #sarcoma benefit from neoadjuvant chemotherapy? The international EA7211/STRASS 2 #ClinicalTrial, led in the US by Dr. Kenneth Cardona, aims to find out. More: bit.ly/EA7211 #leiomyosarcoma #liposarcoma
#FindingsFriday: New insights from the CHAARTED trial, presented at #ASTRO25 - the APUC-6 signature (six androgen production/uptake & conversion genes) may help stratify metastatic #ProstateCancer & refine treatment response. Learn more: bit.ly/43SaV5t #PrecisionMedicine
Validating the APUC-6 Signature in mHSPC from the ECOG-ACRIN E3805 CHAARTED Trial - Xiaolei Shi
UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
bit.ly
November 14, 2025 at 4:47 PM
#FindingsFriday: New insights from the CHAARTED trial, presented at #ASTRO25 - the APUC-6 signature (six androgen production/uptake & conversion genes) may help stratify metastatic #ProstateCancer & refine treatment response. Learn more: bit.ly/43SaV5t #PrecisionMedicine
ICYMI, fascinating finding from #ESMO2025: patients with #cancer who received mRNA COVID vaccines soon after starting #immunotherapy showed stronger immune responses & improved survival. Read the the publication in @nature.com: bit.ly/3LyoZuF #CancerResearch
SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade - Nature
mRNA vaccines targeting SARS-CoV-2 also sensitize tumours to immune checkpoint inhibitors.
bit.ly
November 13, 2025 at 6:03 PM
ICYMI, fascinating finding from #ESMO2025: patients with #cancer who received mRNA COVID vaccines soon after starting #immunotherapy showed stronger immune responses & improved survival. Read the the publication in @nature.com: bit.ly/3LyoZuF #CancerResearch
#FindingsFriday: ICYMI, at #ESMO25 Dr. Janice Mehnert @nyulangone.bsky.social presented results from the STAMP trial, showing that giving pembro after surgery may help prevent #MerkelCellCarcinoma from spreading to distant organs. Promising progress for this rare #SkinCancer! More: bit.ly/49uM4sa
Press Release: Immunotherapy after surgery shows potential in preventing the spread of aggressive skin cancer
A new clinical trials shows that pembrolizumab, a drug that utilizes the body’s immune system to target and eliminate cancer cells, appeared to reduce the risk of distant metastases for an aggressive ...
bit.ly
November 7, 2025 at 1:47 PM
#FindingsFriday: ICYMI, at #ESMO25 Dr. Janice Mehnert @nyulangone.bsky.social presented results from the STAMP trial, showing that giving pembro after surgery may help prevent #MerkelCellCarcinoma from spreading to distant organs. Promising progress for this rare #SkinCancer! More: bit.ly/49uM4sa
The recently reported DREAM3R results show that, for pts w/ pleural #mesothelioma, the addition of durvalumab to chemo = higher tumor response—yet survival benefit is unclear. More research is needed. Read about this collab between @precogonc.bsky.social & @togaanz.bsky.social: bit.ly/47Pw02S
Durvalumab Plus Chemo Yields Inconclusive Results in Advanced Pleural Mesothelioma | OncLive
Durvalumab in combination with chemotherapy produced outcomes consistent with prior studies in patients with advanced pleural mesothelioma.
bit.ly
November 6, 2025 at 3:29 PM
The recently reported DREAM3R results show that, for pts w/ pleural #mesothelioma, the addition of durvalumab to chemo = higher tumor response—yet survival benefit is unclear. More research is needed. Read about this collab between @precogonc.bsky.social & @togaanz.bsky.social: bit.ly/47Pw02S
After being diagnosed with #PancreaticCancer, Steven Merlin found hope through a #clinicaltrial. Now as an ECOG-ACRIN advocate, he shares his perspective on the benefits of clinical trials. Read his inspiring story: bit.ly/beatingtheod...
Beating the odds: Steven Merlin’s journey through pancreatic cancer and clinical trials
An inspiring interview with a 13-year survivor of stage 4 pancreas cancer
bit.ly
November 5, 2025 at 7:21 PM
After being diagnosed with #PancreaticCancer, Steven Merlin found hope through a #clinicaltrial. Now as an ECOG-ACRIN advocate, he shares his perspective on the benefits of clinical trials. Read his inspiring story: bit.ly/beatingtheod...
DYK only 17% of US cancer trials are federally funded—yet they’re far more likely to study rare cancers, pediatric cancers, & multimodality treatments? Public funding = innovation where it’s needed most. More: bit.ly/47kYNME #Oncology #CancerResearch @swog.org
Study Finds Federally Funded Clinical Trials Play a Vital Role in Cancer Research, Especially for Rare and Pediatric Cancers
Although industry-sponsored cancer clinical trials often focus on single-agent drug trials, federally funded cancer clinical trials are more likely to investigate drug combinations with other treatmen...
bit.ly
November 5, 2025 at 2:10 PM
DYK only 17% of US cancer trials are federally funded—yet they’re far more likely to study rare cancers, pediatric cancers, & multimodality treatments? Public funding = innovation where it’s needed most. More: bit.ly/47kYNME #Oncology #CancerResearch @swog.org
The Fall 2025 Group Meeting session recordings are now available on the Attendee Hub Website.
Simply log in with your first name, last name, and the email address you used during registration ➡️ cvent.me/EvkYal #EAOnc
Simply log in with your first name, last name, and the email address you used during registration ➡️ cvent.me/EvkYal #EAOnc
October 29, 2025 at 6:40 PM
The Fall 2025 Group Meeting session recordings are now available on the Attendee Hub Website.
Simply log in with your first name, last name, and the email address you used during registration ➡️ cvent.me/EvkYal #EAOnc
Simply log in with your first name, last name, and the email address you used during registration ➡️ cvent.me/EvkYal #EAOnc
Phase 3 #ClinicalTrial EA8231 is now enrolling! This study is exploring a new treatment approach for patients with treatment-refractory locally-advanced or metastatic #UrothelialCancer. Learn more: bit.ly/ea8231-study... #TargetedTherapy
Now Enrolling: EA8231 Study for Patients With Bladder Cancer That Has Progressed Following Treatment
This phase 3 clinical trial is testing a new treatment approach for patients with treatment-refractory locally-advanced or metastatic urothelial cancer
bit.ly
October 23, 2025 at 5:11 PM
Phase 3 #ClinicalTrial EA8231 is now enrolling! This study is exploring a new treatment approach for patients with treatment-refractory locally-advanced or metastatic #UrothelialCancer. Learn more: bit.ly/ea8231-study... #TargetedTherapy
Day 2 of the #EAOnc Fall 2025 Group Meeting is underway! Let us know which sessions you are heading to today. And don’t miss our General Session at 5:30 PM! 🩺🩻📈
October 23, 2025 at 2:20 PM
Day 2 of the #EAOnc Fall 2025 Group Meeting is underway! Let us know which sessions you are heading to today. And don’t miss our General Session at 5:30 PM! 🩺🩻📈
Thank you to the exceptional presenters and panelists who helped make the Fall 2025 Comis #TranslationalScience Symposium a success: Drs. Jon Steingrimsson, @rhubbbstat.bsky.social, Paul Catalano, Walter Witschey, @jordanberlin5.bsky.social, & Mary Lou Smith!
October 22, 2025 at 8:49 PM
Thank you to the exceptional presenters and panelists who helped make the Fall 2025 Comis #TranslationalScience Symposium a success: Drs. Jon Steingrimsson, @rhubbbstat.bsky.social, Paul Catalano, Walter Witschey, @jordanberlin5.bsky.social, & Mary Lou Smith!
The Comis #TranslationalScience Symposium continues with talks by Dr. Paul Catalano of @danafarber.bsky.social @hsph.harvard.edu & Dr. Walter Witschey @pennmedicine.bsky.social. #AI #imaging
October 22, 2025 at 8:01 PM
The Comis #TranslationalScience Symposium continues with talks by Dr. Paul Catalano of @danafarber.bsky.social @hsph.harvard.edu & Dr. Walter Witschey @pennmedicine.bsky.social. #AI #imaging
First up: talks from Dr. Jon Steingrimsson & Dr. @rhubbbstat.bsky.social, both of @brownbiostatistics.bsky.social, on #AI, #MachineLearning, & #RealWorldData in cancer #ClinicalTrials. More to come!
October 22, 2025 at 7:32 PM
First up: talks from Dr. Jon Steingrimsson & Dr. @rhubbbstat.bsky.social, both of @brownbiostatistics.bsky.social, on #AI, #MachineLearning, & #RealWorldData in cancer #ClinicalTrials. More to come!
Group Co-Chair Dr. Mitch Schnall of @pennmedicine.bsky.social kicks off the Fall 2025 Robert L. Comis Translational Science Symposium, focused on #AI, #RealWorldData, and alternative approaches to phase 2 and 3 therapeutic questions. #EAOnc
October 22, 2025 at 7:15 PM
Group Co-Chair Dr. Mitch Schnall of @pennmedicine.bsky.social kicks off the Fall 2025 Robert L. Comis Translational Science Symposium, focused on #AI, #RealWorldData, and alternative approaches to phase 2 and 3 therapeutic questions. #EAOnc
The Robert L. Comis, MD Translational Science Symposium on Approaches Using #AI and Other Electronic Methods in #ClinicalTrials is underway. Join us in Salon E, 5th Floor! #EAOnc #CancerResearch
October 22, 2025 at 7:09 PM
The Robert L. Comis, MD Translational Science Symposium on Approaches Using #AI and Other Electronic Methods in #ClinicalTrials is underway. Join us in Salon E, 5th Floor! #EAOnc #CancerResearch
Congratulations to the Fall 2025 Edith Peterson Mitchell, MD Travel Scholars! #CancerResearch #ClinicalTrials #EAOnc
October 22, 2025 at 6:03 PM
Congratulations to the Fall 2025 Edith Peterson Mitchell, MD Travel Scholars! #CancerResearch #ClinicalTrials #EAOnc
Congratulations to the early-career researchers selected to present at our annual Young Investigator Symposium! 🩻🩺📈#EAOnc
October 22, 2025 at 3:54 PM
Congratulations to the early-career researchers selected to present at our annual Young Investigator Symposium! 🩻🩺📈#EAOnc
#Immunotherapy after surgery shows potential in preventing spread of aggressive skin cancer. STAMP (EA6174) results at #ESMO25 by Dr. Janice Mehnert of NYU Langone’s Perlmutter Cancer Center. Largest study to date to evaluate pembrolizumab as adjuvant therapy for #MerkelCellCarcinoma bit.ly/4hgQrJg
Press Release: Immunotherapy after surgery shows potential in preventing the spread of aggressive skin cancer
A new clinical trials shows that pembrolizumab, a drug that utilizes the body’s immune system to target and eliminate cancer cells, appeared to reduce the risk of distant metastases for an aggressive ...
bit.ly
October 22, 2025 at 3:22 PM
#Immunotherapy after surgery shows potential in preventing spread of aggressive skin cancer. STAMP (EA6174) results at #ESMO25 by Dr. Janice Mehnert of NYU Langone’s Perlmutter Cancer Center. Largest study to date to evaluate pembrolizumab as adjuvant therapy for #MerkelCellCarcinoma bit.ly/4hgQrJg
The #EAOnc Fall 2025 Group Meeting officially begins today! Looking forward to seeing you in Philadelphia. Check in at the registration desk on the 5th floor before heading to your first session. 🩺🩻📈
October 22, 2025 at 1:00 PM
The #EAOnc Fall 2025 Group Meeting officially begins today! Looking forward to seeing you in Philadelphia. Check in at the registration desk on the 5th floor before heading to your first session. 🩺🩻📈
You may be eligible to participate in a #PancreaticCancer study, EA2192/APOLLO, for patients with #PancreaticCancer that has been surgically removed and has a BRCA1, BRCA2, or PALB2 mutation. Learn more: bit.ly/apollo-trial #pancsm
October 1, 2025 at 4:17 PM
You may be eligible to participate in a #PancreaticCancer study, EA2192/APOLLO, for patients with #PancreaticCancer that has been surgically removed and has a BRCA1, BRCA2, or PALB2 mutation. Learn more: bit.ly/apollo-trial #pancsm
Reposted by ECOG-ACRIN Cancer Research Group
Congratulations to Anthony Letai, MD, PhD, on being named the new director of the National Cancer Institute. His appointment is a testament to our continuing commitment to innovation and collaboration.
Learn more: bit.ly/4pRWiZy
Learn more: bit.ly/4pRWiZy
September 29, 2025 at 9:05 PM
Congratulations to Anthony Letai, MD, PhD, on being named the new director of the National Cancer Institute. His appointment is a testament to our continuing commitment to innovation and collaboration.
Learn more: bit.ly/4pRWiZy
Learn more: bit.ly/4pRWiZy
We congratulate Dr. Anthony Letai on his appointment as NCI Director. His deep scientific expertise & reputation as a collaborative leader make him an excellent choice to drive progress against #cancer. We look forward to working with him! #CancerResearch #ClinicalTrials
September 30, 2025 at 4:45 PM
We congratulate Dr. Anthony Letai on his appointment as NCI Director. His deep scientific expertise & reputation as a collaborative leader make him an excellent choice to drive progress against #cancer. We look forward to working with him! #CancerResearch #ClinicalTrials
Today is #WorldCancerResearchDay! Catch up on the latest
@eaonc.bsky.social research highlights from our August newsletter here ➡️https://bit.ly/aug25research #EAOnc #CancerResearch
@eaonc.bsky.social research highlights from our August newsletter here ➡️https://bit.ly/aug25research #EAOnc #CancerResearch
September 24, 2025 at 4:26 PM
Today is #WorldCancerResearchDay! Catch up on the latest
@eaonc.bsky.social research highlights from our August newsletter here ➡️https://bit.ly/aug25research #EAOnc #CancerResearch
@eaonc.bsky.social research highlights from our August newsletter here ➡️https://bit.ly/aug25research #EAOnc #CancerResearch